title: Topical ibopamine and corticosteroids in the treatment of post-surgery ocular hypotony.
abstract: OBJECTIVE
  The aim of the present preliminary study, performed on post-surgical hypotony, was the evaluation of the effects on ocular hypotony of the concomitant administration of ibopamine and corticosteroids.
  
  
  METHODS
  14 patients (11 males-3 females; mean age 47 years) with ocular hypotony following several vitroretinal surgical intervention in different districts, were enrolled. The inclusion criteria were: mean IOP during tonometric curve equal or lower than 6 mmHg, stable IOP for at least 60 days, ongoing treatment with 0.1% dexamethasone (4 times/day), successful surgical intervention, 2% ibopamine (4 times/day) was added to the corticosteroid therapy for 30-60 days.
  
  
  RESULTS
  Before ibopamine administration, mean IOP was 4.07 mmHg SD 1.71. At the end of the treatment period, mean IOP increased by 89% in comparison to baseline values (+ 3.64 mmHg SD 5.57). This difference was statistically significant (paired t = 2.39; P = 0.03). One month after ibopamine-treatment discontinuation, mean IOP decreased to pre-treatment values (4.86 mmHg SD 3.50).
  
  
  CONCLUSIONS
  The results of the present study, although preliminary, suggest the possibility of a future pharmacological treatment of ocular hypotony with ibopamine, whose rationale is based on the increase of aqueous humor production by stimulating the D1 dopaminergic receptor.
authors.affiliation: Department of Ocular Physio-Pharmacology, Eye Clinic, University La Sapienza, Rome, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Virno
authors.forename: F
authors.initials: F
authors.lastname: De Gregorio
authors.forename: L
authors.initials: L
authors.lastname: Pannarale
authors.forename: L
authors.initials: L
authors.lastname: Arrico
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D001082:Aqueous Humor / Q000378:metabolism; D003846:Deoxyepinephrine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D015814:Ocular Hypotension / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D009883:Ophthalmic Solutions; D011183:Postoperative Complications / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D017447:Receptors, Dopamine D1 / Q000819:agonists; D016896:Treatment Outcome
chemical_list: D018491:Dopamine Agonists; D005938:Glucocorticoids; D009883:Ophthalmic Solutions; D017447:Receptors, Dopamine D1; D003907:Dexamethasone; C023487:ibopamine; D003846:Deoxyepinephrine